Targeted protein degradation is an emerging direction in the field of drug development. 40% of human genes encode extracellular proteins or membrane proteins. The degradation of cell membrane proteins is usually accomplished through lysosomal pathways.Lysosomal targeted chimeras (Lytac technology) are an innovative technology that degrades cell membrane or extracellular proteins, enabling degradation of more “non-prescriptable” targets. The use of relatively non-specific lysosomal degradation pathways to selectively degrade target proteins greatly expands the range of targets. LYTAC technology uses glycan tags to label extracellular proteins to target lysosomes for degradation. First, let’s understand what is a lysosome. The lysosome is a dynamic structure. The shape and size of the lysosome are different in different types of cells. Generally, it is spherical vesicles with a diameter of 0.25~0.8μm, and contains a variety of acid hydrolases, which can decompose various exog...
Integrated Drug Discovery Services- Chemistry, Biology & Preclinical Services